Celgene Shares Fall as Sales of Key Cancer Drug Disappoint

Celgene said quarterly earnings more than tripled but sales of its most important product, cancer drug Revlimid, were smaller than expected.

Net income rose to $57.4 million, or 14 cents a share, from $16 million, or 4 cents a share, a year ago.

Excluding one-time items, the company earned 20 cents a share. Analysts had on average expected earnings of 20 cents a share, according to Thomson Financial.

Revenue rose 61.4 percent to $293.4 million, driven by sales of Revlimid, which came in at $146.2 million. Analysts, however, had on average expected Revlimid sales of $150 million, according to a report by Leerink Swann & Co.

The company reiterated its outlook for 2007 of earnings of $1.00 a share on revenue of about $1.3 billion. Analysts on average expect earnings of $1.04 a share.

Contact U.S. News


    Get the best of CNBC in your inbox

    › Learn More*

Don't Miss

  • An employee weighs a specific amount of marijuana for a customer purchase at the Evergreen Apothecary in Denver.

    The IRS is recommending accountants who help state-recognized, legal marijuana businesses "not be considered unethical."

  • Robo-advisors use algorithms and model portfolios to allocate investments according to a client's particular objectives and risk tolerance.

  • Executives at the Sleep Out around 1:30am in the Covenant House parking lot.

    Ex-Wall Streeter Turney Duff live blogs the Convenant House Sleep Out, where executives and celebrities sleep on the street for a night to raise awareness and money for homeless youth.

U.S. Video